骨髓增生异常综合征患者骨髓细胞周期及CD34+细胞增殖特征的研究

目的　探讨骨髓增生异常综合征 (MDS)患者骨髓细胞周期分布及CD34 细胞增殖特征。方法　碘化丙锭细胞核染色分析MDS、MDS转化的急性髓系白血病 (MDS AML)和原发性AML患者骨髓G0 /G1期、S期和G2 /M期细胞比例 ;免疫荧光双标法分析 3组患者骨髓CD34 细胞中增殖性抗原Ki6 7的表达。结果　与正常组相比 ,MDS患者和原发性AML患者骨髓单个核细胞 (BMM NC)G0 /G1期细胞比例呈明显增高趋势 (92 .4 8± 4 .4 8) %、(96 .71± 2 .75 ) %对 (86 .94± 6 .77) % ](P<0 .0 5 ) ,而MDS组与正常组相比 ,S期和G2 /M期比例呈明显降低趋势 (6 .79± 3.98) %、(0 .86±0 .82 ) %对 (11.97± 7.0 0 ) %、(1.10± 0 .98) % ](P值均 <0 .0 5 )。MDS AML患者与原发性AML相比 ,G0 /G1期细胞为 (91.16± 7.0 9) %对 (96 .71± 2 .75 ) % ,S期为 (7.90± 6 .70 ) %对 (2 .87± 2 .4 9) %、G2 /M期为 (0 .96± 0 .99) %对 (0 .4 3± 0 .4 2 ) % ,S G2 /M期为 (8.84± 7.0 9) %对 (3.34± 2 .83) % (P值均 <0 .0 5 )。MDS患者骨髓CD34 Ki6 7 细胞明显高于正常组 (1.13± 1.10 ) %对 (0 .2 4±0 .2 2 ) % ](P <0 .0 1) ,MDS低危组患者CD34 Ki6 7 细胞为 (0 .5 4± 0 .4 9) % ,明显低于高危组 (1.6 9± 1.6 6 ) % ](P <0 .0

Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes

OBJECTIVE: To study the characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in patients with myelodysplastic syndromes (MDS). METHODS: Propidium iodide staining was used to examine cell cycle parameters (G(0)/G(1), S and G(2)/M) of bone marrow mononuclear cells (BMMNCs) while immunofluorescent double staining and FACS techniques were used to measure Ki67 expression in BM CD34+ cells from normal control, patients with MDS, acute myeloid leukemia preceded by MDS (MDS-AML) and primary AML. RESULTS: There was a statistical up-tendency in G(0)/G(1) phase proportion of BMMNCs whereas a statistical down-tendency in S and G(2)/M phase proportions among normal control, MDS and primary AML. Compared to primary AML, MDS-AML had significantly higher ratios of S (P < 0.05), G(2)/M (P < 0.05) and S + G(2)/M (P < 0.05) phase cells while lower ratio of G(0)/G(1) phase cells (P < 0.05). The proportion of CD34+Ki67+ cells in MDS patients was significantly higher than that in normal control (P = 0.004). So were the percentages of CD34+Ki67+ cells in low-risk (0.54 +/- 0.49)%, P < 0.05] and high-risk MDS patients (1.69 +/- 1.66)%, P = 0.022]. Furthermore, there was statistical difference between low-risk and high-risk MDS (P < 0.05). Compared to normal control and primary AML, MDS-patients had the highest proportion of CD34+Ki67+ cells (16.75 +/- 13.58)%, P < 0.05]. The proportion of CD34+Ki67+ cells in CD34+ cells in MDS patients (48.50 +/- 20.49)%] was significantly higher than that in normal control (27.71 +/- 16.04)%, P < 0.01]. So were the low-risk (51.85 +/- 21.80)%, P = 0.002] and high-risk MDS (43.93 +/- 18.57)%, P < 0.05]. The proportion of CD34+Ki67+ cells in CD34+ cells in MDS-AML patients (60.92 +/- 30.12)%] was the highest, and was statistically higher than that in both normal control (P < 0.01) and primary AML patients (17.01 +/- 15.93)%, P < 0.001]. The proportion of CD34+Ki67+ cells in Ki67+ cells in MDS patients (4.91 +/- 4.68)%, P < 0.01] was significantly higher than that (2.43 +/- 2.37)%] in normal controls. In the low-risk MDS group it was (4.11 +/- 3.94)%, (P > 0.05) and in high-risk MDS group it was (5.76 +/- 5.38)%, (P < 0.05). CONCLUSION: High proportion of G(0)/G(1) cells and G(1) phase arrest occurred in MDS. High proliferation capacity of MDS clone, especially that derived from CD34+ cells, might play an important role in the clonal expansion, diseases deterioration and worse prognosis of MDS.